Wednesday, 2 July 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 02 July 2025
News

Red-hot rivals link up... for now

Posted 27 June 2025 AM

Eli Lilly is touting the success of an antibody in ensuring weight loss from a GLP-1 is from fat rather than muscle, but there's just one quirk - the trial used rival, Novo Nordisk's drug in the combo.

Results presented at the American Diabetes Association annual conference of the placebo-controlled Phase IIb BELIEVE study which enrolled more than 500 patients who were given subcutaneous Wegovy weekly and intravenous monoclonal antibody bimagrumab at weeks 4, 16, 28, and 40 showed that the combination reduced weight by 22.1 per cent at 72 weeks.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (10)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (1)

Devices (1)

Other (10)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.